Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Aug 8;25:232-240. doi: 10.1016/j.msard.2018.08.007. [Epub ahead of print]

PMID:
30121490
2.

Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.

Setayeshgar S, Kingwell E, Zhu F, Zhang X, Zhang T, Marrie RA, Carruthers R, Tremlett H.

Mult Scler Relat Disord. 2018 Jul 9;25:57-60. doi: 10.1016/j.msard.2018.07.012. [Epub ahead of print]

PMID:
30036855
3.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

PMID:
30013178
4.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662. [Epub ahead of print]

PMID:
29979093
5.

Predicting risk of secondary progression in multiple sclerosis: A nomogram.

Manouchehrinia A, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J.

Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667. [Epub ahead of print]

PMID:
29911467
6.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018;51(1-2):1-10. doi: 10.1159/000488799. Epub 2018 May 15.

PMID:
29763935
7.

Can falling infection rates in one country explain rising incidence of autoimmune and allergic diseases in other countries? Caution when (over) interpreting ecological data from disparate areas.

Tremlett H, Rodney R, Lucas R.

Mult Scler Relat Disord. 2018 Apr;21:A3-A5. doi: 10.1016/j.msard.2017.11.001. Epub 2017 Nov 3. No abstract available.

PMID:
29724378
8.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

9.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493. doi: 10.1136/jnnp-2017-317493. [Epub ahead of print]

PMID:
29602795
10.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

PMID:
29523642
11.

Sun exposure over the life course and associations with multiple sclerosis.

Tremlett H, Zhu F, Ascherio A, Munger KL.

Neurology. 2018 Apr 3;90(14):e1191-e1199. doi: 10.1212/WNL.0000000000005257. Epub 2018 Mar 7.

PMID:
29514944
12.

The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset.

Amram O, Schuurman N, Randall E, Zhu F, Saeedi J, Rieckmann P, Yee I, Tremlett H.

Mult Scler Relat Disord. 2018 Apr;21:30-34. doi: 10.1016/j.msard.2018.02.005. Epub 2018 Feb 6.

PMID:
29455071
13.

Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011-2016).

Charron S, McKay KA, Tremlett H.

Mult Scler Relat Disord. 2018 Feb;20:169-177. doi: 10.1016/j.msard.2018.01.021. Epub 2018 Feb 2. Review.

PMID:
29414293
14.

Gut microbiome and pediatric multiple sclerosis.

Tremlett H, Waubant E.

Mult Scler. 2018 Jan;24(1):64-68. doi: 10.1177/1352458517737369.

PMID:
29307301
15.

Effects of physical comorbidities on disability progression in multiple sclerosis.

Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Carruthers R, Wolfson C, Warren S, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

PMID:
29298855
16.

Drug exposure and the risk of multiple sclerosis: A systematic review.

Yong HY, McKay KA, Daley CGJ, Tremlett H.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):133-139. doi: 10.1002/pds.4357. Epub 2017 Dec 6. Review.

PMID:
29210147
17.

Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2017 Dec 12;89(24):2455-2461. doi: 10.1212/WNL.0000000000004716. Epub 2017 Nov 8.

PMID:
29117961
18.

Author response: Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

Tremlett H.

Neurology. 2017 Nov 7;89(19):2022-2023. doi: 10.1212/WNL.0000000000004621. No abstract available.

PMID:
29109136
20.

Concussion may not cause multiple sclerosis.

Wijnands JMA, Tremlett H.

Ann Neurol. 2017 Oct;82(4):651-652. doi: 10.1002/ana.25061. Epub 2017 Oct 14. No abstract available.

PMID:
28976601
21.

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study.

Zhang T, Kingwell E, Zhu F, Petkau J, Kastrukoff LF, Marrie RA, Tremlett H, Evans C.

BMJ Open. 2017 Sep 29;7(9):e018612. doi: 10.1136/bmjopen-2017-018612.

22.

The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings.

Tremlett H, Waubant E.

Neurotherapeutics. 2018 Jan;15(1):102-108. doi: 10.1007/s13311-017-0574-3. Review.

PMID:
28940049
23.

Bayesian analysis of pair-matched case-control studies subject to outcome misclassification.

Högg T, Petkau J, Zhao Y, Gustafson P, Wijnands JM, Tremlett H.

Stat Med. 2017 Nov 20;36(26):4196-4213. doi: 10.1002/sim.7427. Epub 2017 Aug 7.

PMID:
28783882
24.

Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.

McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H.

Neuroepidemiology. 2017;48(3-4):124-130. doi: 10.1159/000477771. Epub 2017 Jul 7.

PMID:
28683461
25.

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.

Kowalec K, Kingwell E, Carruthers R, Marrie RA, Bernatsky S, Traboulsee A, Ross CJD, Carleton B, Tremlett H.

BMJ Open. 2017 Jun 2;7(5):e016276. doi: 10.1136/bmjopen-2017-016276.

26.

Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H; British Columbia Multiple Sclerosis Clinic Neurologists.

Neurology. 2017 Jun 13;88(24):2310-2320. doi: 10.1212/WNL.0000000000004037. Epub 2017 May 12.

27.

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Högg T, Stadnyk K, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Lancet Neurol. 2017 Jun;16(6):445-451. doi: 10.1016/S1474-4422(17)30076-5. Epub 2017 Apr 20.

PMID:
28434855
28.

Increased incidence and prevalence of psoriasis in multiple sclerosis.

Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD.

Mult Scler Relat Disord. 2017 Apr;13:81-86. doi: 10.1016/j.msard.2017.02.012. Epub 2017 Feb 20.

29.

Determinants of neurological disease: Synthesis of systematic reviews.

Krewski D, Barakat-Haddad C, Donnan J, Martino R, Pringsheim T, Tremlett H, van Lieshout P, Walsh SJ, Birkett NJ, Gomes J, Little J, Bowen S, Candundo H, Chao TK, Collins K, Crispo JAG, Duggan T, El Sherif R, Farhat N, Fortin Y, Gaskin J, Gupta P, Hersi M, Hu J, Irvine B, Jahanfar S, MacDonald D, McKay K, Morrissey A, Quach P, Rashid R, Shin S, Sikora L, Tkachuk S, Taher MK, Wang MD, Darshan S, Cashman NR.

Neurotoxicology. 2017 Jul;61:266-289. doi: 10.1016/j.neuro.2017.04.002. Epub 2017 Apr 12. Review.

PMID:
28410962
30.

Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.

Evans C, Marrie RA, Zhu F, Leung S, Lu X, Kingwell E, Zhao Y, Tremlett H.

Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):702-711. doi: 10.1002/pds.4207. Epub 2017 Apr 3.

PMID:
28370875
31.

Primary and secondary progressive MS have a similar age at onset of progression - NO.

Tremlett H, Zhao Y.

Mult Scler. 2017 Apr;23(5):640-642. doi: 10.1177/1352458516684559. No abstract available.

PMID:
28357927
32.

From bugs to brains: The microbiome in neurological health.

McKay KA, Kowalec K, Brinkman F, Finlay BB, Horwitz M, Manges AR, Osborne L, Tremlett H.

Mult Scler Relat Disord. 2017 Feb;12:1-3. doi: 10.1016/j.msard.2016.12.007. Epub 2016 Dec 18.

PMID:
28283098
33.

Infection-related health care utilization among people with and without multiple sclerosis.

Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA, Tremlett H.

Mult Scler. 2017 Oct;23(11):1506-1516. doi: 10.1177/1352458516681198. Epub 2016 Dec 21.

PMID:
28273769
34.

The multiple sclerosis microbiome?

Tremlett H, Waubant E.

Ann Transl Med. 2017 Feb;5(3):53. doi: 10.21037/atm.2017.01.63. No abstract available.

35.

The gut microbiome in human neurological disease: A review.

Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E.

Ann Neurol. 2017 Mar;81(3):369-382. doi: 10.1002/ana.24901. Epub 2017 Mar 20. Review.

PMID:
28220542
36.

Age Related Multiple Sclerosis Severity Score: Disability ranked by age.

Manouchehrinia A, Westerlind H, Kingwell E, Zhu F, Carruthers R, Ramanujam R, Ban M, Glaser A, Sawcer S, Tremlett H, Hillert J.

Mult Scler. 2017 Dec;23(14):1938-1946. doi: 10.1177/1352458517690618. Epub 2017 Feb 3.

37.

THE AUTHORS REPLY.

Karim ME, Gustafson P, Petkau J, Tremlett H.

Am J Epidemiol. 2016 Dec 1;184(11):857-858. Epub 2016 Nov 16. No abstract available.

PMID:
27852602
38.

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.

Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.

Health Technol Assess. 2016 Oct;20(81):1-48.

39.

Genetic variation associated with the occurrence and progression of neurological disorders.

Little J, Barakat-Haddad C, Martino R, Pringsheim T, Tremlett H, McKay KA, van Lieshout P, Walsh SJ, Gomes J, Krewski D.

Neurotoxicology. 2017 Jul;61:243-264. doi: 10.1016/j.neuro.2016.09.018. Epub 2016 Oct 3. Review.

PMID:
27713094
40.

Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis.

Marrie RA, Patten SB, Greenfield J, Svenson LW, Jette N, Tremlett H, Wolfson C, Warren S, Profetto-McGrath J, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis, Blanchard J, Caetano P, Elliott L, Yu BN, Bhan V, Svenson L.

Brain Behav. 2016 Jun 29;6(9):e00493. eCollection 2016 Sep.

41.

Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies.

Karim ME, Petkau J, Gustafson P, Platt RW, Tremlett H; BeAMS Study Group.

Stat Methods Med Res. 2018 Jun;27(6):1709-1722. doi: 10.1177/0962280216668554. Epub 2016 Sep 21.

42.

Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls.

Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil SS, Waubant E; US Network of Pediatric MS Centers.

BMC Neurol. 2016 Sep 21;16(1):182.

43.

Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends.

Marrie RA, Patten S, Tremlett H, Svenson LW, Wolfson C, Yu BN, Elliott L, Profetto-McGrath J, Warren S, Leung S, Jette N, Bhan V, Fisk JD.

Mult Scler Relat Disord. 2016 Jul;8:86-92. doi: 10.1016/j.msard.2016.05.009. Epub 2016 May 11.

44.

Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.

Evans C, Marrie RA, Zhu F, Leung S, Lu X, Melesse DY, Kingwell E, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2016 Jul;8:78-85. doi: 10.1016/j.msard.2016.05.006. Epub 2016 May 7.

45.

Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.

Karim ME, Gustafson P, Petkau J, Tremlett H; Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group.

Am J Epidemiol. 2016 Aug 15;184(4):325-35. doi: 10.1093/aje/kwv445. Epub 2016 Jul 25.

46.

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.

McKay KA, Tremlett H, Patten SB, Fisk JD, Evans C, Fiest K, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Mult Scler. 2017 Apr;23(4):588-596. doi: 10.1177/1352458516657440. Epub 2016 Jul 11.

47.

Disability progression in aggressive multiple sclerosis.

Menon S, Zhu F, Shirani A, Oger J, Freedman MS, Tremlett H.

Mult Scler. 2017 Mar;23(3):456-463. doi: 10.1177/1352458516653273. Epub 2016 Jul 11.

PMID:
27325603
48.

Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.

Zhang T, Kingwell E, De Jong HJ, Zhu F, Zhao Y, Carruthers R, Petkau J, Gustafson P, Oger J, Tremlett H.

Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1150-1159. doi: 10.1002/pds.4031. Epub 2016 May 23.

PMID:
27211481
49.

Gut microbiota in early pediatric multiple sclerosis: a case-control study.

Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S, Waubant E; US Network of Pediatric MS Centers.

Eur J Neurol. 2016 Aug;23(8):1308-1321. doi: 10.1111/ene.13026. Epub 2016 May 13.

50.

Fatigue and Comorbidities in Multiple Sclerosis.

Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, McKay KA, Berrigan LI, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2016 Mar-Apr;18(2):96-104. doi: 10.7224/1537-2073.2015-070.

Supplemental Content

Loading ...
Support Center